Aris Global announced that invivodata has been selected as its preferred partner for ePRO solutions.
invivodata’s ePRO solutions–DiaryPRO® for field-based data collection and SitePRO® for in-clinic based data collection – will provide complementary functionality to Aris Global’s Total Clinical™ suite of integrated solutions, which includes agCapture™ for electronic data capture, ARISg™ for drug safety, agXchange and agClinical™ for clinical trial management. Total Clinical enables companies to enter data once and share across their enterprise. The Total Clinical suite is available on a hosted, managed platform and includes a full range of delivery and support services.
Aris Global’s strategy is to partner with solution providers currently serving the growing ePRO market. invivodata’s ePRO solutions are consistent with Aris Global’s standards of customer service.
“We are very excited about our partnership with invivodata,” said Dr. Sylva H. Collins, vice president, Total Clinical Solutions at Aris Global. “The use of invivodata’s ePRO system brings scientific and regulatory credibility in capturing the patient’s experience in a clinical trial.” “Aris Global’s Total Clinical suite offers value to clinical researchers,” said Doug Engfer, president and CEO at invivodata. “We look forward to working with them and aligning our eClinical solutions to further help life science organizations meet regulatory guidelines, manage risk and improve operational efficiencies.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.